Compare Biocon with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs STERLING BIOTECH - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON STERLING BIOTECH BIOCON /
STERLING BIOTECH
 
P/E (TTM) x 31.2 -0.4 - View Chart
P/BV x 3.7 0.0 26,074.2% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 BIOCON    STERLING BIOTECH
EQUITY SHARE DATA
    BIOCON
Mar-19
STERLING BIOTECH
Dec-13
BIOCON /
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs70711 6,736.2%   
Low Rs5543 16,288.2%   
Sales per share (Unadj.) Rs91.926.8 342.9%  
Earnings per share (Unadj.) Rs16.7-15.0 -111.7%  
Cash flow per share (Unadj.) Rs24.2-5.5 -442.5%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs101.654.9 185.2%  
Shares outstanding (eoy) m600.00267.87 224.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.90.3 2,646.2%   
Avg P/E ratio x37.7-0.5 -8,120.8%  
P/CF ratio (eoy) x26.1-1.3 -2,050.3%  
Price / Book Value ratio x6.20.1 4,899.2%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m378,3301,862 20,321.8%   
No. of employees `0006.11.4 452.8%   
Total wages/salary Rs m11,653547 2,131.1%   
Avg. sales/employee Rs Th8,994.35,303.3 169.6%   
Avg. wages/employee Rs Th1,900.7403.8 470.6%   
Avg. net profit/employee Rs Th1,635.3-2,959.0 -55.3%   
INCOME DATA
Net Sales Rs m55,1447,181 767.9%  
Other income Rs m1,44443 3,389.7%   
Total revenues Rs m56,5887,223 783.4%   
Gross profit Rs m15,883947 1,677.4%  
Depreciation Rs m4,4782,543 176.1%   
Interest Rs m7094,377 16.2%   
Profit before tax Rs m12,140-5,931 -204.7%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,123-1,924 -110.3%   
Profit after tax Rs m10,026-4,007 -250.2%  
Gross profit margin %28.813.2 218.4%  
Effective tax rate %17.532.4 53.9%   
Net profit margin %18.2-55.8 -32.6%  
BALANCE SHEET DATA
Current assets Rs m48,22814,335 336.4%   
Current liabilities Rs m30,37649,809 61.0%   
Net working cap to sales %32.4-494.0 -6.6%  
Current ratio x1.60.3 551.7%  
Inventory Days Days68403 16.9%  
Debtors Days Days86171 50.1%  
Net fixed assets Rs m64,13055,432 115.7%   
Share capital Rs m3,000268 1,119.8%   
"Free" reserves Rs m57,98013,935 416.1%   
Net worth Rs m60,98014,701 414.8%   
Long term debt Rs m15,7669,478 166.3%   
Total assets Rs m121,92473,988 164.8%  
Interest coverage x18.1-0.4 -5,105.5%   
Debt to equity ratio x0.30.6 40.1%  
Sales to assets ratio x0.50.1 466.0%   
Return on assets %8.80.5 1,757.8%  
Return on equity %16.4-27.3 -60.3%  
Return on capital %16.8-6.4 -260.7%  
Exports to sales %28.125.9 108.6%   
Imports to sales %18.90.2 11,099.4%   
Exports (fob) Rs m15,5061,860 833.7%   
Imports (cif) Rs m10,39912 85,237.7%   
Fx inflow Rs m15,5061,860 833.7%   
Fx outflow Rs m10,39925 41,779.8%   
Net fx Rs m5,1071,835 278.3%   
CASH FLOW
From Operations Rs m11,5461,719 671.8%  
From Investments Rs m-7,138-3,148 226.7%  
From Financial Activity Rs m-2,4171,426 -169.5%  
Net Cashflow Rs m2,103-3 -61,852.9%  

Share Holding

Indian Promoters % 40.4 33.9 119.2%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 0.0 -  
FIIs % 10.7 9.9 108.1%  
ADR/GDR % 0.0 16.9 -  
Free float % 19.9 39.3 50.6%  
Shareholders   109,995 21,482 512.0%  
Pledged promoter(s) holding % 0.0 55.9 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  GLENMARK PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare BIOCON With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Plunged 2% Today(Closing)

Indian share markets witnessed heavy selling pressure today despite the US administration saying it would bring a stimulus package even without the opposition's support.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 27, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS